FDA Clearance Tracker · P910023-S270
CADENCE FAMILY OF ICDS
Last checked: Nov 20, 2026Latest source record: Mar 9, 2012 (this decision)Source: openFDAMethods & limitations
Decided
Mar 9, 2012
Approved
Time to decision
234 days
Received Jul 19, 2011. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P910023-S270
- Device name
- CADENCE FAMILY OF ICDS
- Applicant
- ABBOTT MEDICAL
- Applicant location
- Sylmar, CA
- Received
- Jul 19, 2011
- Decided
- Mar 9, 2012
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P910023
Device type
- Device class
- Class III
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE ADDITION OF THE CORVUE THORACIC IMPEDANCE MONITORING FEATURE IN THE UNIFY, FORTIFY AND QUADRA FAMILY OF DEVICES.
Source documents
Other decisions for ABBOTT MEDICAL
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P260019 · Decided Oct 27, 2026 · 180 days after receipt
Device type: Para-device leak occluder (SJT) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.